Müller J, Wissel J, Kemmler G, Voller B, Bodner T, Schneider A, Wenning G K, Poewe W
University Hospital of Neurology, Innsbruck, Austria. University Hospital of Psychiatry, Innsbruck, Austria.
J Neurol Neurosurg Psychiatry. 2004 May;75(5):749-53. doi: 10.1136/jnnp.2003.013441.
To develop and test a questionnaire for measuring quality of life in patients with craniocervical dystonia.
A 29-item pool was developed based on semi-structured interviews of patients with cervical dystonia (CD) and blepharospasm (BSP). This preliminary questionnaire was administered to 203 consecutive patients with CD and BSP from Austrian dystonia and botulinum toxin outpatient clinics. For scale generation, a combination of exploratory factor and cluster analysis was applied. This resulted in the 24-item version of the instrument (CDQ-24) based on five subscales: Stigma, Emotional wellbeing, Pain, Activities of daily living, and Social/family life. The validity and reliability of the CDQ-24 was assessed in 231 consecutive patients with CD and BSP different from those examined with the preliminary questionnaire. This second survey included the CDQ-24, a generic QoL instrument (SF-36) and clinical rating scales. Sensitivity to change was analysed in 51 previously untreated (de novo) patients four weeks and one year following the first botulinum toxin treatment.
Internal consistency reliability was satisfactory for all subscales, with values of Cronbach's alpha ranging from 0.77 to 0.89. The CDQ-24 subscales showed moderate to high correlations with those SF-36 subscales measuring similar aspects (Pearson's correlation r = 0.50-0.73; p<0.001, each). Sensitivity to change was confirmed by highly significant improvements of all CDQ-24 subscores in the de novo patients from baseline to four week follow up. One year follow up data revealed a stable improvement.
The CDQ-24 is the first fully validated and disease specific questionnaire to evaluate quality of life of patients with cervical dystonia and blepharospasm and we propose its use in clinical trials as well as in daily clinical practice.
开发并测试一份用于测量颅颈肌张力障碍患者生活质量的问卷。
基于对颈部肌张力障碍(CD)和眼睑痉挛(BSP)患者的半结构化访谈,编制了一个包含29个条目的题库。这份初步问卷被发放给来自奥地利肌张力障碍与肉毒毒素门诊的203例连续的CD和BSP患者。为了生成量表,采用了探索性因素分析和聚类分析相结合的方法。由此产生了基于五个子量表的24个条目版本的工具(CDQ - 24):耻辱感、情绪健康、疼痛、日常生活活动以及社交/家庭生活。在231例与接受初步问卷调查的患者不同的连续CD和BSP患者中评估了CDQ - 24的有效性和可靠性。第二次调查包括CDQ - 24、一份通用生活质量工具(SF - 36)和临床评定量表。对51例首次接受治疗(初发)的患者在首次肉毒毒素治疗后四周和一年时分析了其对变化的敏感性。
所有子量表的内部一致性信度均令人满意,克朗巴哈α系数值在0.77至0.89之间。CDQ - 24子量表与SF - 36中测量相似方面的子量表显示出中度至高相关性(皮尔逊相关系数r = 0.50 - 0.73;各p < 0.001)。初发患者从基线到四周随访时,所有CDQ - 24子评分均有高度显著改善,证实了对变化的敏感性。一年随访数据显示改善稳定。
CDQ - 24是首个经过充分验证的、针对疾病的问卷,用于评估颈部肌张力障碍和眼睑痉挛患者的生活质量,我们建议在临床试验以及日常临床实践中使用它。